D. Miller

发表

Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies.

D. Miller, R. Coleman, R. Drake, 2004, Gynecologic oncology.

Pharmacotherapy of endometrial cancer

D. Miller, T. Herzog, Nicanor I Barrena Medel, 2009, Expert opinion on pharmacotherapy.

New therapies for advanced, recurrent, and metastatic endometrial cancers

R. Wenham, D. Mutch, D. Miller, 2017, Gynecologic Oncology Research and Practice.

The Ovarian Tumor Index predicts risk for malignancy

D. Miller, D. Twickler, D. McIntire, 1999, Cancer.

Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer.

Jae-Weon Kim, W. Small, D. Miller, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer.

W. E. Richards, D. Matei, W. Small, 2019, The New England journal of medicine.

Tumor size in endometrial cancer

A. Rademaker, D. Miller, J. Schink, 1991, Cancer.

Safety and efficacy of pemetrexed in gynecologic cancers: A systematic literature review

C. Obasaju, I. Vergote, D. Miller, 2013 .

Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endometrial carcinomas.

Jingqin Luo, P. Goodfellow, D. Mutch, 2010, Gynecologic oncology.

Urinary Bladder Cancer

D. Miller, C. Wai, D. Miller, 2002, Clinical obstetrics and gynecology.

Factors influencing primary treatment of midline vulvar cancers.

J. Lea, D. Miller, S. Conrad, 2016, Gynecologic oncology.

Pembrolizumab plus lenvatinib combination therapy for advanced endometrial carcinoma

A. Spirtos, D. Miller, Christopher A Walker, 2023, Expert review of anticancer therapy.

Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.

Robert S Mannel, Michael L Pearl, D. Miller, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hormonal therapy in epithelial ovarian cancer

Gautam G. Rao, D. Miller, G. Rao, 2006, Expert review of anticancer therapy.

Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.

H. Lenz, D. Miller, R. Mannel, 2005, Gynecologic oncology.

Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study.

D. Miller, S. Waggoner, J. Schilder, 2005, Gynecologic oncology.

Phase II evaluation of three‐day topotecan in recurrent platinum‐sensitive ovarian carcinoma

D. Miller, S. Lentz, J. Blessing, 2003, Cancer.

Immunologic Characterization of Tumor Markers in Human Ovarian Cancer Cell Lines

J. Mathis, W. Kutteh, D. Miller, 1996, The Journal of the Society for Gynecologic Investigation: JSGI.

Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial Cancer

Gloria S. Huang, M. Sherman, L. Brinton, 2021, Cancer Epidemiology, Biomarkers & Prevention.

Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study

R. Burger, D. Cella, P. Disaia, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma

J. Lea, D. Miller, D. Castrillon, 2020, The American journal of surgical pathology.

Fertility-sparing surgery in 101 women with adenocarcinoma in situ of the cervix.

D. Miller, J. Schorge, P. Gehrig, 2007, Gynecologic oncology.

PRO: All patients with serous and clear cell carcinomas of the endometrium should receive chemotherapy as part of their treatment

D. Miller, T. Boren, D. Miller, 2010 .

Should All Patients with Serous and Clear Cell Endometrial Carcinoma Receive Adjuvant Chemotherapy?

D. Miller, T. Boren, D. Miller, 2010, Women's health.

Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.

D. Bodurka, D. Miller, J. Schorge, 2008, Gynecologic oncology.

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

D. Matei, A. Berchuck, E. Ratner, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.

K. Yonemori, S. Pignata, I. Ray-Coquard, 2022, The New England journal of medicine.

Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial

D. Mutch, A. Secord, D. Miller, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study.

C. Muller, D. Miller, R. Coleman, 2022, Gynecologic oncology.

726MO Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775)

B. Monk, H. Mackay, D. Miller, 2021, Annals of Oncology.

S. Pignata, I. Ray-Coquard, N. Colombo, 2021, Journal of Clinical Oncology.

Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).

D. Cella, D. Miller, Takashi Matsumoto, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second-line lenvatinib in patients with recurrent endometrial cancer.

I. Vergote, D. Miller, Y. Funahashi, 2020, Gynecologic oncology.

A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer.

S. Pignata, C. Aghajanian, R. Penson, 2019, Journal of Clinical Oncology.

A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study.

D. Miller, N. Spirtos, J. Rotmensch, 2011, Gynecologic oncology.

LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment.

Antonio L Amelio, Kwok-Kin Wong, Ralph J DeBerardinis, 2015, The Journal of clinical investigation.

A Phase II Trial of Stereotactic Ablative Radiotherapy as a Boost for Locally Advanced Cervical Cancer.

R. Timmerman, J. Lea, D. Miller, 2019, International journal of radiation oncology, biology, physics.

Progress in endometrial cancer: Contributions of the former Gynecologic Oncology Group.

D. Miller, M. Randall, V. Filiaci, 2020, Gynecologic oncology.

Lymph node metastasis in endometrioid adenocarcinomas of the uterine corpus with occult cervical involvement.

J. Lea, D. Miller, T. Boren, 2012, Gynecologic oncology.

Advanced endometrial cancer: is lymphadenectomy necessary or sufficient?

D. Miller, D. Miller, 2006 .

Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study.

D. Cella, H. Thaler, S. King, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG Oncology trial.

W. Richards, D. Mutch, A. Secord, 2019, Journal of Clinical Oncology.

NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Ovarian Cancer, Version 2.2020

Malley, D. Matei, A. Berchuck, 2021 .

An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.

D. Tritchler, P. Goodfellow, D. Mutch, 2018, Gynecologic oncology.

The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American Society for Radiation Oncology evidence-based guideline.

B. Erickson, Benjamin D. Smith, A. Damato, 2014, Practical radiation oncology.

Serial genomic analysis of endometrium supports the existence of histologically indistinct endometrial cancer precursors

J. Lea, D. Miller, I. Cuevas, 2021, The Journal of pathology.

Somatic LKB1 Mutations Promote Cervical Cancer Progression

Kwok-Kin Wong, N. Sharpless, D. Kwiatkowski, 2009, PloS one.

Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

M. Birrer, D. Mutch, D. Miller, 2019, Gynecologic oncology.

Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis.

J. Minna, C. Muller, J. Lea, 2004, American journal of obstetrics and gynecology.

Differences at Presentation and Treatment of Testicular Cancer in Hispanic Men: Institutional and National Hospital-based Analyses.

Y. Lotan, V. Margulis, A. Sagalowsky, 2018, Urology.

Clinical Evidence: Metastases can Metastasize

D. Miller, J. Mansour, R. Schwarz, 2012, World journal of oncology.

Bacteriology and Treatment of Malodorous Lower Reproductive Tract in Gynecologic Cancer Patients

D. Miller, R. Coleman, V. V. von Gruenigen, 2000, Obstetrics and gynecology.

Chemo- and radiotherapy in adjuvant management of optimally debulked endometrial cancer.

D. Miller, G. Fleming, M. Randall, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study

D. Miller, Takashi Matsumoto, G. Fleming, 2012 .

A Phase 3 Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High-Risk, Early-Stage Endometrial Cancer: A Gynecology Oncology Group Study

W. Small, D. Miller, C. Yashar, 2017 .

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.

B. Monk, D. Matei, A. Oza, 2019, The Lancet. Oncology.

Other primary malignancies in patients with uterine corpus malignancy.

D. Miller, R. Coleman, Jacquelyn B Delin, 2004, American journal of obstetrics and gynecology.

Mismatch Repair Protein Expression in Endometrioid Intraepithelial Neoplasia/Atypical Hyperplasia: Should We Screen for Lynch Syndrome in Precancerous Lesions?

J. Lea, D. Miller, D. Castrillon, 2019, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.

D. Miller, J. Fiorica, J. Sorosky, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.

D. Matei, A. Berchuck, M. Dwyer, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Endometrial Endometrioid Carcinomas Associated with Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor

D. Miller, L. Copeland, J. Albores–Saavedra, 2000, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Long‐term results of interstitial implant in locally advanced cervical cancer: A retrospective study of 50 cases

T. Carmody, P. Nguyen, B. John, 1996 .

An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275

N. Horowitz, D. Miller, K. Moxley, 2020, Gynecologic oncology.

Locally Advanced Cervical Cancer: Outcomes With Variable Adherence to Treatment

J. Lea, D. Miller, D. McIntire, 2016, American journal of clinical oncology.

A Phase II Trial of Leuprolide Acetate in Patients with Advanced Epithelial Ovarian Carcinoma: A Gynecologic Oncology Group Study

D. Miller, M. Brady, R. Barrett, 1992, American journal of clinical oncology.

Is comprehensive surgical staging needed for thorough evaluation of early-stage ovarian carcinoma?

D. Miller, T. Boren, S. Wingo, 2012, American journal of obstetrics and gynecology.

Hypoalbuminemia is a Predictive Factor for Fistula Formation in Recurrent Cervical Cancer

J. Lea, D. Miller, D. Richardson, 2017, American Journal of Clinical Oncology.

Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study.

D. Miller, J. Schilder, A. Munkarah, 2005, Gynecologic oncology.

Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.

D. Miller, M. Method, F. Muggia, 2004, Gynecologic oncology.

Surgical and systemic management of endometrial cancer: an international survey

S. Kehoe, I. Vergote, D. Miller, 2015, Archives of Gynecology and Obstetrics.

Gynecologic oncology group trials in uterine corpus malignancies: recent progress.

D. Miller, L. King, D. Miller, 2008, Journal of gynecologic oncology.

The Significance of Para-Aortic Nodal Size and the Role of Adjuvant Systemic Chemotherapy in Cervical Cancer: An Institutional Experience

J. Lea, D. Miller, A. Bailey, 2018, American journal of clinical oncology.

Adenomyofibroma of the Endometrium with Skeletal Muscle Differentiation

D. Miller, S. Milchgrub, A. Hameed, 2000, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Baseline platelet count and body weight as predictors of early dose modification in the quadra trial of niraparib monotherapy for the treatment of heavily pretreated (≥4th line), advanced, recurrent high-grade serous ovarian cancer

B. Monk, A. Oza, J. Berek, 2019, Gynecologic Oncology.

Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study.

W. E. Richards, D. Matei, D. Mutch, 2021, Gynecologic oncology.

Current practice patterns in nodal evaluation and adjuvant treatment of advanced stage endometrioid endometrial cancer: An SGO survey

J. Lea, D. Miller, J. E. Parker, 2020, Gynecologic oncology reports.

The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncology Group (GOG) study.

Danielle M. Enserro, D. Cella, D. Miller, 2019, Gynecologic oncology.

A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma.

D. Matei, D. Mutch, D. Miller, 2017 .

The Role of Lymphadenectomy in Endometrial Cancer

D. Miller, S. Kehoe, D. Miller, 2011, Clinical obstetrics and gynecology.

Patients with endometrial cancer at risk for lymphatic metastasis should undergo pelvic and periaortic lymphadenectomy as part of their initial surgery

D. Miller, 2017, Cancer.

Adjuvant External Radiation Impacts Outcome of Pelvis-limited Stage III Endometrial Carcinoma: A Multi-institutional Study

Xian-Jin Xie, A. Christie, M. Folkert, 2017, American journal of clinical oncology.

Ovarian Preservation in Stage I Low-Grade Endometrial Stromal Sarcomas

Beth Y Karlan, Richard Drake, B. Karlan, 2005, Obstetrics and gynecology.

Third-line Salvage Chemotherapy for Recurrent Carcinoma of the Cervix is Associated With Minimal Response Rate and High Toxicity

J. Lea, D. Richardson, S. Kehoe, 2017, American journal of clinical oncology.

Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group.

Jubilee Brown, L. Ramondetta, D. Miller, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study.

B. Monk, D. Miller, J. Fiorica, 2006, Gynecologic oncology.

Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer.

Jingqin Luo, Daniel E Deatherage, Daniel E. Deatherage, 2009, Cancer research.

A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.

D. Mutch, D. Miller, K. Leslie, 2014, Gynecologic oncology.

Pre‐operative core muscle index in combination with hypoalbuminemia is associated with poor prognosis in advanced ovarian cancer

J. Lea, D. Miller, S. Conrad, 2018, Journal of surgical oncology.

Survival outcomes after recurrence in endometrioid compared to papillary serous/clear cell carcinoma of the uterus

J. Lea, C. Nagel, D. Richardson, 2012 .

Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival.

R. Wenham, J. Lea, D. Miller, 2002, Gynecologic oncology.

Stage IVA cervical cancer: outcomes of disease related complications and treatment

J. Lea, B. R. Khulpateea, M. Carlson, 2020, International Journal of Gynecological Cancer.

Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study.

Danielle M. Enserro, J. Blay, K. Robison, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer

K. Yonemori, S. Pignata, I. Ray-Coquard, 2022, Obstetrical & Gynecological Survey.

Osteopontin as an Adjunct to CA 125 in Detecting Recurrent Ovarian Cancer

R. Berkowitz, S. Skates, D. Cramer, 2004 .

Gestational trophoblastic disease among Hispanic women: a 21-year hospital-based study.

Gautam G. Rao, D. Miller, J. Schorge, 2006, Gynecologic oncology.

Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis.

J. Thigpen, P. DiSilvestro, J. Java, 2016, Gynecologic oncology.

Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer

Samuel C. Mok, R. Berkowitz, S. Skates, 2004, Clinical Cancer Research.

Isolated para-aortic nodal recurrence after treatment of early stage cervical carcinoma.

J. Lea, D. Miller, S. Holloway, 2023, Gynecologic oncology.

Endocervical curettage at conization to predict residual cervical adenocarcinoma in situ.

J. Lea, D. Miller, J. Schorge, 2002, Gynecologic oncology.

A Phase 2 Evaluation of Irofulven as Second-line Treatment of Recurrent or Persistent Intermediately Platinum-Sensitive Ovarian or Primary Peritoneal Cancer: A Gynecologic Oncology Group Trial

C. Muller, M. Shahin, D. Miller, 2010, International Journal of Gynecologic Cancer.

Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775

B. Monk, K. Yonemori, I. Ray-Coquard, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol.

D. Mutch, S. Waggoner, J. Boggess, 2017, Gynecologic Oncology.

The opinions and practices of providers toward the sexual issues of cervical cancer patients undergoing treatment.

J. Lea, D. Miller, D. Richardson, 2016, Gynecologic oncology.

ZoptEC: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (NCT01767155).

A. Oza, R. Wenham, H. Gabra, 2018 .

A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: Angiopoietin-2 as a predictive marker for clinical outcomes.

I. Vergote, T. Pintér, Y. Funahashi, 2013 .

Silencing of HPV 18 Oncoproteins With RNA Interference Causes Growth Inhibition of Cervical Cancer Cells

J. Minna, N. Sunaga, C. Muller, 2007, Reproductive Sciences.

Flow Cytometric Evaluation of Early Invasive Cervical Cancer

A. Rademaker, K. Bauer, D. Miller, 1993, Obstetrics and gynecology.

A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study.

D. Miller, S. Waggoner, S. Lentz, 2002, Gynecologic oncology.

Response to “Towards implementation of sexual healthcare”

J. Lea, D. Richardson, M. Carlson, 2017, Gynecologic oncology reports.

Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma.

J. Lea, D. Miller, J. Schorge, 2003, Gynecologic oncology.

GOG 3007, a randomized phase II (RP2) trial of everolimus and letrozole (EL) or hormonal therapy (medroxyprogesterone acetate/tamoxifen, PT) in women with advanced, persistent or recurrent endometrial carcinoma (EC): A GOG Foundation study

D. Miller, R. Coleman, Joan L. Walker, 2018, Gynecologic Oncology.

Implications of EGFR inhibition in ovarian cancer cell proliferation.

M. Peyton, H. Shigematsu, J. Lea, 2008, Gynecologic oncology.

A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology.

D. Miller, R. Higgins, J. Blessing, 2009, Gynecologic oncology.

P16 as a molecular biomarker of cervical adenocarcinoma.

R. Ashfaq, J. Lea, D. Miller, 2004, American journal of obstetrics and gynecology.

Clinical applications of hormonal therapy in ovarian cancer

Gautam G. Rao, D. Miller, G. Rao, 2005, Current treatment options in oncology.

Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited, high-grade leiomyosarcoma: A phase III GOG study.

Danielle M. Enserro, J. Blay, K. Robison, 2018 .

A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study.

P. Fracasso, H. Cárdenes, D. Miller, 2012, Gynecologic oncology.

Correlation of cone biopsy with findings at radical hysterectomy and use of adjuvant radiation therapy.

J. Lea, D. Miller, T. Boren, 2012, Gynecologic oncology.

Cervical adenocarcinoma survival among Hispanic and white women: a multicenter cohort study.

J. Lea, D. Miller, J. Schorge, 2003, American journal of obstetrics and gynecology.

Early-stage cervical adenocarcinoma treated by surgical intent: the role of para-aortic lymph node dissection.

J. Lea, D. Miller, J. Schorge, 2002, Gynecologic oncology.

Prognostic Significance of Nodal Location and Ratio in Stage IIIC Endometrial Carcinoma Among a Multi-Institutional Academic Collaboration

Xian-Jin Xie, A. Christie, M. Folkert, 2018, American journal of clinical oncology.

A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients.

C. Takimoto, A. Patnaik, G. Fleming, 2020 .

Chromosome 4 deletions are frequent in invasive cervical cancer and differ between histologic variants.

A. Gazdar, R. Ashfaq, C. Muller, 2000, Gynecologic oncology.

Pathology Slide Review in Gynecologic Oncology

D. Miller, R. Coleman, S. Lifshitz, 1998, Obstetrics and gynecology.

Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: A propensity-score matched analysis.

Y. Lotan, V. Margulis, A. Sagalowsky, 2018, Urologic oncology.

Ectopic production and localization of beta-human chorionic gonadotropin in lymphoepithelioma-like carcinoma of the cervix: a case report.

C. Muller, G. Lindberg, R. Coleman, 2000, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

The impact of body mass index on surgical outcomes of total laparoscopic radical hysterectomy in women with early-stage cervical cancer

J. Lea, D. Miller, D. Manders, 2017 .

A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer

K. Yonemori, S. Pignata, I. Ray-Coquard, 2021, Gynecologic Oncology.

Malignant ovarian germ cell tumor - role of surgical staging and gonadal dysgenesis.

J. Lea, D. Miller, D. Richardson, 2014, Gynecologic oncology.

Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis.

S. Waggoner, M. Kelly, A. Wolfson, 2021, Gynecologic oncology.

Ovarian involvement in endometrioid adenocarcinoma of uterus.

J. Lea, D. Miller, A. Bailey, 2015, Gynecologic oncology.

Emphasis on Systemic Therapy in Women With Pelvic Bone Metastasis at Time of Diagnosis of Cervical Cancer

J. Lea, D. Miller, K. Albuquerque, 2018, American journal of clinical oncology.